These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23899496)

  • 1. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials.
    Kishi T; Mukai T; Matsuda Y; Moriwaki M; Iwata N
    J Psychiatr Res; 2013 Nov; 47(11):1557-63. PubMed ID: 23899496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Oya K; Kishi T; Iwata N
    Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials.
    Zheng W; Li XB; Shi ZM; Yang XH; Cai DB; Ng CH; Ungvari GS; Liu WJ; Wu YJ; Wang YY; Ning YP; Xiang YT
    Pharmacopsychiatry; 2020 Jan; 53(1):5-13. PubMed ID: 31207653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Iwata N
    CNS Drugs; 2013 Sep; 27(9):731-41. PubMed ID: 23812802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.
    Oya K; Matsuda Y; Matsunaga S; Kishi T; Iwata N
    Eur Arch Psychiatry Clin Neurosci; 2016 Aug; 266(5):439-50. PubMed ID: 26303414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials.
    Zheng W; Xiang YT; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Correll CU
    Acta Psychiatr Scand; 2016 Nov; 134(5):385-398. PubMed ID: 27585549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia.
    Galling B; Vernon JA; Pagsberg AK; Wadhwa A; Grudnikoff E; Seidman AJ; Tsoy-Podosenin M; Poyurovsky M; Kane JM; Correll CU
    Acta Psychiatr Scand; 2018 Mar; 137(3):187-205. PubMed ID: 29431197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials.
    Kishi T; Hirota T; Iwata N
    Eur Arch Psychiatry Clin Neurosci; 2013 Dec; 263(8):633-41. PubMed ID: 23605347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.
    Correll CU; Maayan L; Kane J; Hert MD; Cohen D
    J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
    Kishi T; Mukai T; Matsuda Y; Iwata N
    Neuromolecular Med; 2014 Mar; 16(1):61-9. PubMed ID: 23896722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Iwata N
    J Psychiatr Res; 2013 Sep; 47(9):1143-9. PubMed ID: 23692933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
    Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
    Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
    Poyurovsky M; Faragian S; Fuchs C; Pashinian A
    Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis.
    Sakuma K; Matsunaga S; Nomura I; Okuya M; Kishi T; Iwata N
    Psychopharmacology (Berl); 2018 Aug; 235(8):2303-2314. PubMed ID: 29785555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.
    Dold M; Li C; Gillies D; Leucht S
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1023-33. PubMed ID: 23602690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials.
    Srisurapanont M; Suttajit S; Maneeton N; Maneeton B
    J Psychiatr Res; 2015 Mar; 62():38-47. PubMed ID: 25619176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.
    Kishi T; Matsuda Y; Iwata N
    Psychopharmacology (Berl); 2017 Jul; 234(14):2113-2125. PubMed ID: 28508107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Okuyama Y; Oya K; Matsunaga S; Kishi T; Iwata N
    Neuropsychiatr Dis Treat; 2016; 12():3221-3236. PubMed ID: 28008259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials.
    Zheng W; Cai DB; Yang XH; Li L; Zhang QE; Ng CH; Ungvari GS; Li XB; Ning YP; Xiang YT
    J Psychiatr Res; 2018 Aug; 103():244-251. PubMed ID: 29906709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.
    Galling B; Roldán A; Rietschel L; Hagi K; Walyzada F; Zheng W; Cao XL; Xiang YT; Kane JM; Correll CU
    Expert Opin Drug Saf; 2016 May; 15(5):591-612. PubMed ID: 26967126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.